01.08.25 -- Alternatives To CRISPR-Cas9: Nucleases For Next-Gen Therapy

Alternatives to CRISPR-Cas9 address limitations like delivery challenges and off-target effects. Emerging nucleases offer improved specificity, smaller sizes, and therapeutic applications.

The project manager's sphere of influence extends beyond the project team, encompassing the organization, industry, and professional discipline.

Gain insight into how a global pharmaceutical company successfully transferred their cell therapy assays across international locations.

The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development.

In this presentation, we introduce the human Airway Lung-Chip, which can model influenza virus infection and evolution in vitro and evaluate therapeutics for both influenza and SARS-CoV-2.

Find answers to frequently asked questions about selecting appropriate controls, so you can confidently design your next plasmid-based experiment.

Third-generation lentiviral vectors enable efficient gene delivery, but purification challenges limit in vivo applications. Monolithic columns and advanced assays show promise for downstream processes.

Researchers developed base-edited CAR T cells and CD45-edited stem cells to create universal blood cancer immunotherapy, showcasing efficacy while minimizing toxicity using electroporation technology.

Learn how the knowledge generated by a deep and thorough analysis of chemokine receptors on natural killer (NK) cells can be helpful to scientists studying certain cancers and diseases.